These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7479388)

  • 1. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
    Huber PR; Schmid HP; Mattarelli G; Strittmatter B; van Steenbrugge GJ; Maurer A
    Prostate; 1995 Oct; 27(4):212-9. PubMed ID: 7479388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors.
    Hilz H; Noldus J; Hammerer P; Buck F; Lück M; Huland H
    Eur Urol; 1999 Oct; 36(4):286-92. PubMed ID: 10473986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin.
    Huber PR; Mattarelli G; Strittmatter B; van Steenbrugge GJ; Schmid HP; Maurer A
    Prostate; 1995 Sep; 27(3):166-75. PubMed ID: 7567696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease.
    España F; Martínez M; Sánchez-Cuenca J; Vera CD; Estellés A; Jiménez-Cruz JF
    Eur Urol; 1996; 30(4):512-8. PubMed ID: 8977078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
    Saedi MS; Hill TM; Kuus-Reichel K; Kumar A; Payne J; Mikolajczyk SD; Wolfert RL; Rittenhouse HG
    Clin Chem; 1998 Oct; 44(10):2115-9. PubMed ID: 9761243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular forms of prostate-specific antigen and their clinical significance].
    Hilz H
    Urologe A; 1995 Jul; 34(4):275-82. PubMed ID: 7545841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoenzymes of human prostate acid phosphatase.
    Chu TM; Wang MC; Merrin C; Valenzuela L; Murphy GP
    Oncology; 1978; 35(5):198-200. PubMed ID: 724198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.
    Tanaka M; Suzuki Y; Takaoka K; Murakami S; Suzuki N; Shimazaki J
    Int J Urol; 1999 Dec; 6(12):600-6. PubMed ID: 10609542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
    Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
    Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.